RhumbLine Advisers
IPHA

RhumbLine Advisers’s Innate Pharma IPHA Stock Holding History

RhumbLine Advisers’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.06K Sell
4,734
-470
-9% -$767 ﹤0.01% 3862
2025
Q4 		$9.11K Buy
5,204
+4,734
+1,007% +$9.14K ﹤0.01% 3865
2025
Q3 		$916 Hold
470
– – ﹤0.01% 4027
2025
Q2 		$822 Sell
470
-205
-30% -$416 ﹤0.01% 4051
2025
Q1 		$1.2K Hold
675
– – ﹤0.01% 4019
2024
Q4 		$1.25K Buy
675
+470
+229% +$883 ﹤0.01% 4061
2024
Q3 		$469 Hold
205
– – ﹤0.01% 4123
2024
Q2 		$397 Hold
205
– – ﹤0.01% 4297
2024
Q1 		$590 Hold
205
– – ﹤0.01% 4181
2023
Q4 		$574 Hold
205
– – ﹤0.01% 4196
2023
Q3 		$518 Hold
205
– – ﹤0.01% 4230
2023
Q2 		$643 Buy
+205
New +$630 ﹤0.01% 4312

Other funds holding IPHA

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

RhumbLine Advisers's IPHA Position: Q1 2026 in Review

RhumbLine Advisers reduced its Innate Pharma (IPHA) stake by 9% in Q1 2026, selling an estimated $767 and leaving 4,734 shares worth $6.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3862.

RhumbLine Advisers first reported a position in IPHA in Q2 2023 and has held it in 12 quarters since. The position peaked at $9.11K in Q4 2025. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

  • RhumbLine Advisers held 4,734 shares of Innate Pharma worth $6.06K as of Q1 2026.
  • RhumbLine Advisers sold 470 Innate Pharma shares in Q1 2026, an estimated $767.
  • Innate Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3862 holding.
  • RhumbLine Advisers first reported a position in Innate Pharma in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Innate Pharma position peaked at $9.11K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.